Panel Discussion: Ushering in a New Era of Disease-Modifying Therapies in AD & PD – Beyond Amyloid & α-Synuclein
- Exploring emerging mechanisms such as mitochondrial stress, ferroptosis, and microglial TREM2 to diversify therapeutic strategies and expand opportunities
- Evaluating how mixed-modality combinations may outperform single antibodies, offering more robust and durable disease-modifying potential
- Implementing biomarker panels to de-risk first-in-human trials, enabling smarter patient selection and stronger regulatory confidence